The economics of cancer care remain a major concern as practices try to figure out how to deal with the cost of providing cancer care, said Sibel Blau, MD, medical oncologist, Northwest Medical Specialties, and president and CEO, Quality Cancer Care Alliance (QCCA).
The economics of cancer care remain a major concern as practices try to figure out how to deal with the cost of providing cancer care, said Sibel Blau, MD, medical oncologist, Northwest Medical Specialties, and president and CEO, Quality Cancer Care Alliance (QCCA).
Transcript
Despite being in a pandemic, life and disease both go on. What are some of the other top issues that community oncology practices are focused on right now?
I think, if you're asking my opinion, and what's in my mind, among all the other regular stuff that we deal with every day, I worry about the economics and how it's going to affect us in the near future. What I'm talking about is the next 5 years or so. We know that there is an expected deficit in Medicare. Medicare [Part] A was supposed to run out of money by 2026. There are some reports that this could, because of the decline in the crisis, the health economic crisis that we're living in, this might come down to 2022, or 2023.
We are in the middle of developing value-based care organizations and alternative payment plans trying to figure out a way to deal with the cost of everything—anything from drugs to hospitalizations. But the reality is, we still—cancer just like you said, cancer or the disease does not go away. It still goes on. We have to be able to provide care to these patients.
So, I think our biggest challenge really is, other than doing our daily operations and trying to keep up with the load of the patients and adjust as we go, is to think about the future and how we're going to adapt ourselves to now going from OCM [Oncology Care Model] to OCF [Oncology Care First]. and the future payment plans where we can focus on improving the care, improving the quality of care, and reducing the cost. So, we can actually continue to provide care for our patients in the future.
And the Medicare population is growing. Baby boomers are becoming 65 in these years. In 2029, 20% of the baby boomers—American population—will be Medicare eligible. So, we have we have a big problem in front of us. So, as community oncology, I think we do have a responsibility and obligation to think about not just taking care of the patients that walk into the doors, but really try to think how we can contribute to this system by using innovative and efficient tools and methods to help our patients and help our practices.
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Many Patients Stop GLP-1s Before Reaching Target Dose: Hamlet Gasoyan, PhD
June 19th 2025Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite provider follow-up and efforts to manage side effects, says Hamlet Gasoyan, PhD, Cleveland Clinic.
Read More